Mock-up Updates Study Tags (field_study_tags) - Any - ADEQUATE Blog Call-outs CLIN-Net CoMeCT COVID-19 Data Ecraid ECRAID-Base EPI-Net EPOXI Mpox NeoDeco Partners People PIPELINE POS-ARI-ER POS-ARI-PC POS-cUTI POS-Disease X POS-VAP Primary Care PRUDENCE RECLAIM RECOVERY REMAP-CAP SNAP SOS Covid Training 8.06.2022 Ground-breaking tool helps limit antimicrobial resistance spread across borders An easy-to-use, freely accessible AMR Travel Tool developed by Ecraid's epidemiology network. 17.05.2022 New POS-Disease X publication: Team tackles acute hepatitis mystery An unusually high number of cases of unexplained acute hepatitis among young children has been puzzling health experts. 10.05.2022 Ecraid introduces new COO Nils Visser Utrecht, 10 May 2022 – The Ecraid Management Board is pleased to announce the appointment of Nils Visser as its new Chief Operat… 9.05.2022 Developing sustainable solutions to fight COVID-19 and COVID-like illness The ECRAID-Prime study is the first-of-its-kind multi-country, adaptive platform trial in primary care across Europe. 29.04.2022 Ecraid brought insights and expertise to ECCMID 2022 Highlights from Ecraid's first appearance at ECCMID. 13.04.2022 Ecraid begins its fight against infectious diseases Load More
8.06.2022 Ground-breaking tool helps limit antimicrobial resistance spread across borders An easy-to-use, freely accessible AMR Travel Tool developed by Ecraid's epidemiology network.
17.05.2022 New POS-Disease X publication: Team tackles acute hepatitis mystery An unusually high number of cases of unexplained acute hepatitis among young children has been puzzling health experts.
10.05.2022 Ecraid introduces new COO Nils Visser Utrecht, 10 May 2022 – The Ecraid Management Board is pleased to announce the appointment of Nils Visser as its new Chief Operat…
9.05.2022 Developing sustainable solutions to fight COVID-19 and COVID-like illness The ECRAID-Prime study is the first-of-its-kind multi-country, adaptive platform trial in primary care across Europe.
29.04.2022 Ecraid brought insights and expertise to ECCMID 2022 Highlights from Ecraid's first appearance at ECCMID.
